Scandinavian ChemoTech receives final patent approval in the EU for the tumour specific control unit in our TSE™ platform
The Company has received the final approval for its EU patent which includes the tumour specific control unit and safety features that are crucial for our TSE platform. The innovation is designed to reduce the side effects which normally occur with older electroporation and ablative technologies.
This patent further strengthens ChemoTech’s TSE technology and protects the crucial control unit that generates the unique TSE pulse. The control unit helps the treating physicians of both IQwave™ and vetIQure™ to reduce necros1 and improve apoptosis2.
The concept of TSE is to establish a better balance between necrosis and apoptosis by enhancing the uptake of chemotherapy and avoiding unwanted destruction that can generate inflammation.
” Obtaining the final approval for this innovation in the EU was, although expected, very important for the continued protection of our TSE platform and makes us even more unique. This will play out well to further diversify us from older technologies.” - says Mohan Frick CEO and co-founder ChemoTech
For more information, please contact:
Mohan Frick, CEO
+46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se
1 Necrosis is the death of body tissue. It occurs when too little blood flows to the tissue. This can be from injury, radiation, or chemicals. Necrosis cannot be reversed (https://medlineplus.gov/ency/article/002266.htm)
2 Apoptosis refers to a process that is called “programmed cell death” where the cell starts to kill itself. (https://www.genome.gov/genetics-glossary/apoptosis)
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
